Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: Data for the period 1987-2003 from the Swedish hospital discharge registry

European Heart Journal

Volumn 30, Issue 6, 2009, Pages 671-678

  Shafazand, Masoud ^a   Schaufelberger, Maria ^a   Lappas, Georgios ^a   Swedberg, Karl ^a   Rosengren, Annika ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Gender; Heart failure; Ischaemic; Mortality; Non ischaemic

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REGISTER; SEX RATIO; SURVIVAL RATE; SWEDEN;

ADULT; AGE DISTRIBUTION; AGED; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS; SEX DISTRIBUTION; SEX FACTORS; SURVIVAL ANALYSIS; SWEDEN;

EID: 65349180721     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn541     Document Type: Article

References (40)

1. Eriksson H. Heart failure: a growing public health problem. J Intern Med 1995;237: 135-141.
2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cordiol 1993;22A:6A-13A.
3. Redfield MM, Jacobsen SJ, Bunett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic JAMA 2003;289:194-202.
4. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults, J Am Geriotr Soc 1997;45:968-974.
5. Ryden-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med 1999;246:275-284.
6. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 2004;25:300-307.
7. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 1990;150:769-773.
8. Stewart S, Maclntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospitalization for heart failure in Scotland, 1990-1996. An epidemic that has reached its peak? Eur Heart J 2001;22:209-217.
9. Kannel WB, Ho K, Thorn T Changing epidemiological features of cardiac failure, Br Heart J 1994;72(Suppl. 2):S3-S9.
10. Garg R, Yusuf S. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450- 1456.
11. McMurray JJ. Major beta blocker mortality trials in chronic heart failure: a critical review. Heart 1999;82(Suppl. 4):IV14-IV22.
12. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelsen EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.
13. Pitt B, Rajagopalan S. Aldosterone receptor antagonists for heart failure: current status, future indications. Cleve Clin J Med 2006;73:257-260, 264-268.
14. Strömberg A, MårtenssonJ. Gender differences in patients with heart failure. Eur J Cardiovasc Nurs 2003;2:7-18.
15. Hogg K, Swedberg K, McMurryJ. Heart failure with preserved left ventricular systolic function. Epidemiology, clinical characteristics and prognosis. J Am Coll Cardiol 2004;43:317-327.
16. Dauterman KW, Go AS, Rowell R, Gebretsadik T, Gettner S, Massie BM. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals, J Card Fail 2001;7:221-228.
17. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piñna IL, Granger CB, Ostergren J, Michelsen EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;115:3111-3120.
18. Cleland JG, Swedberg K, Follat F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, WidimskyJ, Freemantle N, Eastaugh J, Manson J, Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1 and part 2: patient characteristics and diagnosis. Eur Heart J 2003;24:442-474.
19. Ingelsson E, Ämlöv J, Sundström J, Lind L The validity of a diagnosis of heart failure in a hospital discharge registers. Eur J Heart Fail 2005;7:787-791.
20. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol 2001;30(Suppl. 1):S30-S34.
21. Maclntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finalayson A, PellJP, Evans CJ, Mcmurray JJ. Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-1131.
22. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murahito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402.
23. Komajda M. Improving outcomes in chronic heart failure. Drugs Today (Barc ) 2006; 42(Suppl. C):29-36.
24. MCMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006; 155:985-991.
25. Strömberg A, Mårtensson J, Fridlund B, Levin L-Å, Jan-Erik K, Dahlström U. Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure. Eur Heart J 2003;24:1014-1023.
26. Stewart S, Horowitz John D. Home-based intervention in congestive heart failure, long-term implications on readmission and survival. Circulation 2002;105: 2861 -2866.
27. Remme WJ, Swedberg K. The task force for the diagnosis and treatment of chronic heart failure: guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
28. Eriksson H, Wilhelmsen L, Caidahl K, Svärdsudd K. Epidemiology and prognosis of heart failure. Z Kardioi 1991;80(SuppL 8):1-6.
29. Rosén M, Alfredsson L, Hammar N, Kahan T, Spetz CL, Ysberg AS. Attack rate, mortality and case fatality for acute myocardial infarction in Sweden during 1987-95. Results from the National AMI Register in Sweden. J Intern Med 2000;248: 159-164.
30. Daviglus ML, Lloyd-Jones DM, Pirzada A. Preventing cardiovascular disease in the 21st century: therapeutic and preventive implication of current evidence. Am J Cordiovosc Drugs 2006;6:87-101.
31. Jaber WA, Lennon RJ, Mathew V, Holmes DR Jr, Lerman A, Rihal CS. Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator. J Am Coll Cardiol 2005;46:1473-1478.
32. Wilhelmsen L, Welin L, Svärdsudd K, Wedel H, Eriksson H, Hansson PO, Rosengren A. Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models, J Intern Med 2008;263:636-643.
33. Salomaa V, Rosamond W, Mahonen M. Decreasing mortality from acute myocardial infarction: effect of incidence and prognosis. J Cordiovosc Risk 1999;6:69-75.
34. Rosengren A, Eriksson H, Larsson B, Svärdsudd K, Tibblin G, Welin L, Wilhelmsen L. Secular changes in cardiovascular risk factors over 30 years in Swedish men aged 50, the study of men born in 1913, 1923, 1933 and 1943. J Intern Med 2000;247:111-118.
35. Mosterd A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE, Levy D. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999; 340:1221-1227.
36. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, Evans A, Ferrario M, Tuomilehto J. Estimation of contribution of changes in classic risk factors to trends in coronary event rates across the WHO MONICA Project populations. Lancet 2000;355:675-687.
37. Lenzen MJ, Rosengren A, Scholte op Reimer W, Follath F, Boersma E, Simoons M, Cleland J, Komajda M. Management of patients with heart failure in clinical practice: differences between men and women. Heart 2008;94:e10.
38. Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004;6:663- 668.
39. Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J 1999;138:835-842.
40. Rathore SS, Foody JM, Wang Y, Herrin J, Masoudi FA, Havranek EP, Ordin DL, Krumholz HM. Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am Heart J 2005;149:121-128.